Valuation: Gilead Sciences, Inc.

Market Cap 167B 146B 136B 125B 235B 15,932B 239B 1,617B 633B 7,901B 626B 613B 27,299B P/E 2026 *
-48.4x
P/E 2027 * 17x
Enterprise Value 176B 155B 144B 133B 249B 16,849B 253B 1,710B 669B 8,356B 662B 648B 28,870B EV / Sales 2026 *
5.8x
EV / Sales 2027 * 5.16x
Free-Float
99.88%
Yield 2026 *
2.45%
Yield 2027 * 2.54%
1 day-0.21%
1 week+2.83%
Current month+6.08%
1 month+6.09%
3 months+4.02%
6 months-3.96%
Current year+9.19%
1 week 127.61
Extreme 127.61
136.26
1 month 124.19
Extreme 124.19
140.61
Current year 116.88
Extreme 116.88
157.29
1 year 108.46
Extreme 108.4601
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Sell

Chief Financial Officer

-3,000 0.0002%
7/15/26 Sell

Executive/Senior Manager

-3,000 0.0002%
7/1/26 Sell

Chief Executive Officer

-15,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-0.20%+2.83%+17.33%+76.02% 167B
+0.30%+5.39%+60.66%+169.66% 1,089B
+0.60%+4.98%+59.63%+60.18% 643B
+1.45%+5.48%+39.73%+78.62% 465B
-1.69%+8.81%+39.38%+33.67% 359B
-0.51%+3.51%+36.97%+42.46% 303B
+1.50%+3.40%+17.71%+17.41% 267B
+0.79%+5.81%-2.55%-38.10% 226B
-0.44%+7.03%+29.07%+67.32% 212B
+0.34%+2.01%+4.20%-29.78% 144B
Average +0.22%+4.54%+30.21%+47.75% 387.5B
Weighted average by Cap. +0.30%+4.94%+41.81%+78.35%

Financials

2026 *2027 *
Net sales 30.42B 26.7B 24.86B 22.87B 42.87B 2,907B 43.6B 295B 115B 1,442B 114B 112B 4,980B 32.3B 28.34B 26.39B 24.28B 45.51B 3,086B 46.29B 313B 123B 1,530B 121B 119B 5,287B
Net income -3.39B -2.98B -2.77B -2.55B -4.78B -324B -4.86B -32.87B -12.87B -161B -12.73B -12.45B -555B 9.78B 8.58B 7.99B 7.35B 13.78B 934B 14.02B 94.81B 37.11B 463B 36.71B 35.92B 1,601B
Net Debt 9.6B 8.42B 7.84B 7.21B 13.52B 917B 13.76B 93.05B 36.42B 455B 36.03B 35.25B 1,571B -
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-07-29 $134.12 -0.15% 2,116,428
26-07-28 $134.32 +2.91% 6,947,167
26-07-27 $130.52 +0.94% 4,953,801
26-07-24 $129.31 -1.18% 5,529,741
26-07-23 $130.86 +0.40% 6,299,287
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
134.32USD
Average target price
157.15USD
Spread / Average Target
+17.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock